Generate:Biomedicines and Novartis Announce Partnership
Generate:Biomedicines is thrilled to share its new collaboration with Novartis, aiming to harness its cutting-edge generative AI platform to discover protein therapeutics. This partnership is set to address various disease areas by developing potential first- and best-in-class therapeutic molecules.
Revolutionizing Drug Discovery with Generative AI
This collaboration will utilize The Generate Platform, which blends machine learning with high-throughput experimental validation. By tapping into Novartis's deep expertise in target biology and biologics development, both companies are eager to speed up the drug discovery process and create innovative therapeutics. This joined effort marks a major leap forward in pharmaceutical research.
Leadership Insights
Fiona Marshall, President of Biomedical Research at Novartis, expressed her excitement about the partnership. She pointed out the promise generative AI holds in enhancing biologics discovery, saying, “This collaboration offers an opportunity to leverage the unique strengths of our respective companies...to bring forward new medicines with transformative potential for patients.”
Striving for Better Medicines
Mike Nally, Chief Executive Officer of Generate:Biomedicines, also recognized the significance of their partnership. He noted, “Partnering with a world-leading drug discovery and development organization like Novartis allows us to broaden the use of our cutting-edge generative biology platform.” Their collaboration specifically focuses on solving unmet medical needs, with the goal of producing innovative solutions more promptly.
Financial Details of the Collaboration
Per the agreement, Generate:Biomedicines will receive an upfront payment of $65 million from Novartis. This total includes $15 million meant for equity purchases. Additionally, Generate is positioned to earn more than $1 billion in milestone payments, along with tiered royalties that could reach low double digits. Specifics on the number of targets or therapy areas haven’t been released, creating a sense of anticipation surrounding the partnership.
What is Generative Biology?
Generative biology represents a significant shift in how therapies are created. By utilizing generative AI, this method develops entirely new therapeutic molecules specifically targeting biological processes vital for disease treatment. The variety of these molecules can range from short peptides to complex antibodies and cytokines. Generative biology aims to overcome the hurdles of traditional drug discovery methods, crafting precise solutions to meet therapeutic demands.
A Closer Look at Generate:Biomedicines
Generate:Biomedicines is at the helm of technology-driven therapeutic development. With an emphasis on machine learning, biological engineering, and medicine, the company focuses on creating superior medicines to tackle challenges that conventional drug development methods struggle with. Established in 2018 by Flagship Pioneering, Generate is committed to moving from traditional drug discovery practices to more innovative drug generation strategies.
Frequently Asked Questions
What is the main goal of the collaboration between Generate and Novartis?
The collaboration aims to leverage generative AI for the discovery and development of novel protein therapeutics across multiple diseases.
How much funding is included in the collaboration agreement?
Generate will receive an upfront payment of $65 million, which includes $15 million for equity purchases.
What is generative biology?
Generative biology refers to the use of generative AI to create novel therapeutic molecules that target specific biological processes associated with diseases.
What potential benefits does the collaboration promise for patients?
The partnership aims to enhance the pace of drug discovery and development, potentially resulting in new medicines with transformative effects for patients.
When was Generate:Biomedicines founded?
Generate:Biomedicines was founded in 2018 by Flagship Pioneering, focusing on programmable biology to develop better medicines more effectively.
